Journal of Molecular Graphics and ModellingBioinformaticsPeer-reviewed journal article
Ligandability Assessment of the LAG-3 D1 Domain Enables Discovery of a Small-Molecule Inhibitor
Abstract
LAG-3 is an emerging immune checkpoint whose extracellular D1 domain engages MHC class II through a broad protein-protein interface traditionally considered difficult to modulate with small molecules. To evaluate the ligandability of this region, we combined 100-ns molecular dynamics (MD) simulations, structure-based virtual screening, and biophysical and biochemical assays. MD sampling of the isolated D1 domain revealed a recurrent, transient cavity adjacent to the MHCII-binding surface. A representative pocket-open conformation was used to screen a [~]10,240-compound diversity library, yielding a single validated hit, N05. N05 bound the D1 domain with micromolar affinity measured by microscale thermophoresis (Kd = 59.2 {micro}M, TRIC/MST channel) and by spectral-shift detection (Kd = 56.1 {micro}M), and it partially inhibited the LAG-3/MHCII interaction (EC50 = 42.9 {micro}M; maximal inhibition [~]76%). A 30-ns MD simulation of the LAG-3-N05 complex showed stable ligand engagement within the MD-identified cavity and consistent stabilizing interactions with residues forming the pocket. These results demonstrate that the LAG-3 D1 domain possesses an accessible, dynamically formed binding site capable of accommodating small molecules, providing a structural and biophysical foundation for future exploration of LAG-3 ligandability. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=151 SRC="FIGDIR/small/692800v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@177b446org.highwire.dtl.DTLVardef@1dc9efdorg.highwire.dtl.DTLVardef@14a2d6aorg.highwire.dtl.DTLVardef@ebca69_HPS_FORMAT_FIGEXP M_FIG C_FIG Overview of the computational and experimental workflow used to identify and validate a small-molecule binder of the LAG-3 D1 domain.
- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 4th percentile
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- From Virtual Screens to Cellular Target Engagement: New Small Molecule Ligands for the Immune Checkpoint LAG-3
Natalie S. Fuchs, Laura Calvo‐Barreiro, … Moustafa Tarek Gabr·ACS Medicinal Chemistry LettersPeer-reviewed·Oct 15, 2024
- Discovery and Optimization of LAG-3-Targeted Small Molecules via DNA-Encoded Chemical Library (DEL) Screening for Cancer Immunotherapy
Somaya A. Abdel‐Rahman, Laura Calvo‐Barreiro, … Moustafa Tarek Gabr·Journal of Medicinal ChemistryPeer-reviewed·Aug 20, 2025
- Development and characterization of Novel Small Molecule Inhibitors Targeting LAG-3 Protein
Oleksandr Yakovenko, Alireza Baradaran‐Heravi, Steven J.M. Jones·bioRxiv·Aug 29, 2025
- Design and Validation of the First-in-Class PROTACs for Targeted Degradation of the Immune Checkpoint LAG-3
Nelson García-Vázquez, Somaya A. Abdel‐Rahman, … Moustafa Tarek Gabr·Bioorganic & Medicinal Chemistry LettersPeer-reviewed·Oct 5, 2025
- Structure-Based Design of Small-Molecule Inhibitors of Human Interleukin-6
Ankit Joshi, Zhousheng Xiao, … Madhulika Gupta·MoleculesPeer-reviewed·Jul 10, 2025
- Targeting interactions between the Galectin-3 intrinsically disordered and structured domains based on long time-scale accelerated molecular dynamics
S. Bhattacharya, M. Zhang, … N. Heisterkamp·bioRxiv·Sep 27, 2021